STOCK TITAN
  1. Home
  2. News
  3. RARE

Ultragenyx Pharmaceutical Inc. - RARE STOCK NEWS

Welcome to our dedicated news page for Ultragenyx Pharmaceutical (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharmaceutical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ultragenyx Pharmaceutical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ultragenyx Pharmaceutical's position in the market.

News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. reports the grant of 44,965 restricted stock units to newly hired non-executive officers under Nasdaq Listing Rule 5635(c)(4). The awards were approved by the compensation committee and granted under the Ultragenyx Employment Inducement Plan. The restricted stock units vest over four years, with 25% of the shares vesting annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announces positive interim Phase 1/2 data for GTX-102 in Angelman Syndrome patients, showing rapid and significant improvement across multiple domains. Expansion Cohorts exhibit consistent or better results than Dose-escalation Cohorts, with long-term benefits observed. Investor call scheduled at 8:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.79%
Tags
clinical trial
-
News
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. reschedules conference call to discuss new clinical data from GTX-102 in patients with Angelman Syndrome for April 15, 2024. The Phase 1/2 study results will be presented at the American Academy of Neurology Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.79%
Tags
none
News
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (RARE) to discuss new clinical data from GTX-102 Phase 1/2 study for Angelman syndrome at AAN Meeting. The company will present preclinical and clinical data, including new efficacy and safety data from expansion cohorts. The investigational antisense oligonucleotide, GTX-102, targets and inhibits UBE3A antisense transcript. Abstracts are available online, with additional data to be presented at the conference. Conference call scheduled for April 17 to discuss the latest findings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.3%
Tags
conferences
-
News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. granted 13,020 restricted stock units to eight new non-executive officers under the Ultragenyx Employment Inducement Plan. The awards vest over four years, with 25% of shares vesting annually, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
-
News
Ultragenyx to Participate at Investor Conferences in March
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (RARE) will participate in three investor conferences in March 2024, including the 44th Annual Cowen Healthcare Conference, Leerink Partners Global Biopharma Conference, and Barclays 26th Annual Global Healthcare Conference. Management will engage in fireside chats and 1x1 meetings to discuss the company's focus on developing therapies for rare genetic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
conferences
News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (RARE) granted 10,995 restricted stock units to nine new non-executive officers under the Employment Inducement Plan. The awards vest over four years, with 25% vesting annually, subject to continuous employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
-
News
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. reported a total revenue of $434 million in 2023, with Crysvita revenue of $328 million and Dojolvi revenue of $71 million. The company provided financial guidance for 2024, expecting total revenue between $500 million and $530 million, Crysvita revenue between $375 million and $400 million, and Dojolvi revenue between $75 million and $80 million. Ultragenyx also disclosed a year-end 2023 cash balance of $777 million and projected net cash used in operations to be less than $400 million for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
earnings
-
News
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. will host a conference call to discuss its financial results and corporate update for the fourth quarter and the year ending December 31, 2023. The live and replayed webcast of the call will be available through the company’s website. Participants can register for the live call and access the replay for 3 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
conferences earnings
News
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (RARE) announced positive data from the pivotal Transpher A and long-term follow-up studies for UX111 (ABO-102) AAV gene therapy for Sanfilippo syndrome type A. The data demonstrated rapid and sustained decreased levels of heparan sulfate (HS) in cerebrospinal fluid (CSF), correlated with improved long-term cognitive development. Treatment resulted in a 51% reduction in CSF-HS levels and a 63% reduction in CSF HS exposure over time. Cognitive function showed stability or gains in 16 of 17 patients, with a significant correlation between CSF HS exposure and cognitive function. The most frequently reported treatment-related adverse events were mild or moderate. The study enrolled 28 patients across 3 dose Cohorts at 5 sites in 3 countries, with the high dose Cohort 3 (3x1013 vg/kg) showing promising results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
none
Stock RARE logo
Ultragenyx Pharmaceutical Inc.

Nasdaq:RARE

RARE Rankings

#1392 Ranked by Market Cap
#3255 Ranked by Stock Gains
N/A Ranked by Dividends

RARE Stock Data

3.87B
72.17M
4.11%
101.15%
4.76%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Novato

About RARE

ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d